CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Andreı̈ Szöke

OPENALEX: A5057841284↗ORCID: 0000-0003-2973-7981↗

Affiliations

Organizations

Assistance Publique – Hôpitaux de Parisauthorship · FR Centre Hospitalier Universitaire Henri-Mondorauthorship · FR Centro de Investigación Biomédica en Red de Salud Mentalauthorship · ES Fondation FondaMentalauthorship · FR Hôpital Albert-Chenevierauthorship · FR Hôpitaux Universitaires Henri-Mondorauthorship · FR Hospital General Universitario Gregorio Marañónauthorship · ES Insermauthorship · FR Institut Mondor de Recherche Biomédicaleauthorship · FR Instituto de Salud Carlos IIIauthorship · ES King's College Londonauthorship · GB Paris-Est Supauthorship · FR Université Clermont Auvergneauthorship · FR Université Paris-Est Créteilauthorship · FR

Public evidence

8 connected articles

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC Cannabis use and cognitive biases in people with first-episode psychosis and their siblings.2024 · Europe PMC Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.2023 · Europe PMC First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.2021 · PubMed Central Open Access The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.2021 · PubMed Central Open Access Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study.2021 · PubMed Central Open Access The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.2019 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Andreı̈ Szöke - Medical Cannabis Research Engine